Overcoming the problem of radiation resistant hypoxic cells continues to be a major focus of interest in radiation biology and oncology (Coleman, 1988; Dische, 1989; Hirst, 1986; Guichard, 1989; Brown, 1989) . One of the most effective ways of improving the oxygenation and radiation response of experimental tumours is by the administration of fluorocarbon emulsions prior to a period of breathing high oxygen content gases (Teicher & Rose, 1984; Song et al., 1985; Rockwell, 1985; Song et al., 1987; Teicher & Rose, 1986; Rockwell et al., 1986; Sasai et al., 1989; Thomas et al., 1989) . However, the enhancements of radiation response obtained using such an approach indicate that complete elimination of the radioresistant hypoxic cell population is not achieved.
One explanation for the residual pockets of radiobiological hypoxia that exist in tumours during fluorocarbon/oxygen therapy is that hypoxia in tumours does not result solely from chronic diffusion limitations as described by Thomlinson and Gray (1955) , but can occur from transient fluctuations in microregional blood flow Intalglietta et al., 1977; Brown, 1979; Sutherland & Franko, 1980; Chaplin et al., 1987) . If blood flow stops or blood vessel occlusion occurs in a tumour microregion, many of the resulting hypoxic cells are situated at a distance from a functional vessel much greater than the estimated oxygen diffusion distance of 50-230 microns (Thomlinson & Gray, 1955; Tannock, 1972) . In such a situation, increasing the oxygen carrying capacity of the blood would not be an effective method of reoxygenation. There is now clear evidence that radiobiological hypoxia in at least two experimental tumours can result from transient fluctuations in microregional blood flow Chaplin et al., 1986; Trotter et al., 1989; Chaplin et al., 1989; Minchinton et al., 1990) . If (Horsman et al., 1987; Horsman et al., 1988; Horsman et al., 1989) , have indicated that its activity, at least in part, results from its ability to reduce the occurrence of acute hypoxia within a solid tumour (Teicher et al., 1989 (Chaplin et al., 1983 ) using 270 kVp X-rays at a dose rate of 2.9Gy min-'.
Carbogen breathing Animals that were injected with Fluosol DA were placed in their individual plexiglass/lead boxes in the irradiation set-up. A plexiglass cover was then placed over the set-up and clipped into place. The system was then gassed with Carbogen (95% 02, 5% C02) for 1 h prior and during irradiation.
Preparation of tumour cell suspensions The animals were sacrificed and tumours excised 18-20 h after irradiation. Following excision, the tumours were washed with PBS, chopped using crossed scalpels, and weighed. The resulting fragments, after being washed with PBS, were disaggregated by gentle agitation for 30 min with an enzyme cocktail of trypsin (0.2%), DNAase (0.05%) and collagenase (0.05%) at 37°C. The resulting cell suspension was filtered through polyester mesh (50 pm pore size), cen- trifuged, and the cell pellet resuspended in medium. Cell suspensions were routinely counted with the aid of a haemocytometer enabling tumour cell yield to be ascertained. The mean cell yields for tumours in this series of experiments were 6.1 x l07g-I of tissue for the SCCVII tumours and 1.1 x 108 g-of tissue for the KHT tumours.
Measurement of cell survival Tumour cell viability was assessed using the soft agar clonogenic assay described previously (Courtenay, 1976 Fraction of surviving cells/tumour = S F x cell yield/g treated cell yield/g untreated We have chosen to analyse the cell survival data in terms of enhancement factors at a given dose of radiation. Enhancement ratios calculated from slope changes would not be appropriate for comparing strategies which may actually be improving oxygenation of the tumour. The effect of such therapies would be a downward displacement of the terminal portion of the survival curve with no change in slope. In addition, since Nicotinamide does show a modest ability to enhance radiation damage in vitro, presumably through some repair inhibition process, a simple calculation of the hypoxic fraction from a downward shift of the survival curve would also not provide a suitable analysis.
Enhancement factors were derived from the data by comparing the best fit regression lines through the data. From these lines the radiation dose required without pretreatment to give the same survival level as 12 Gy with drug pretreatment was obtained. The ratio of these doses is designated as the enhancement factors at 12 Gy i.e. EF (12) . Since the derivation is not statistically vigorous we have, in addition to EF (12) values, calculated the statistical significance of differences in cell survival seen in drug pretreated and in X-ray only groups using two tailed t-tests.
Fluorescence activated cell sorting studies Details of the sorting procedures have been described in detail previously . A brief description is given here. The fluorescent bisbenzamide stain Hoechst 33342 (10 ig g-') was injected intravenously via the lateral tail vein 20 min prior to irradiation. For animals being gassed with Carbogen, injection was achieved via an indwelling catheter. Immediately after irradiation tumours were excised, washed in cold PBS, chopped on ice and disaggregated. Cells were sorted into two fractions, each representing 10% of the total cell population, one containing the brightest cells and one containing the dimmest cells.
Growth delay studies Growth delay was determined using groups of 6-8 mice bearing subcutaneous SCCVII tumours. Tumour volumes were calculated from three orthogonal diameters. Measurements were made just prior to treatment and then subsequently three times a week. The time taken for the individual tumours in each treatment group to reach twice their original volume was determined. Thus, the mean and standard error of the time for each dose group could be calculated. For each radiation dose group the statistical significance of growth delay values of drug pretreated compared to X-ray only groups was assessed using two tailed t-tests.
Results
The effect of Nicotinamide administered at a dose of 1.0 mg g-' 60 min before various doses of X-rays on tumour cell survival can be seen in Figure 1 . Nicotinamide significantly increases radiation response at all radiation dose levels, with an EF (12) (12) of 1.1 being evident. However, in this series of experiments the enhanced cell killing induced by pretreatment with Fluosol DA/Carbogen did not attain significance at any dose level. The effect of combining Nicotinamide and Fluosol DA/Carbogen treatment on radiation response is shown in Figure 2 . It can clearly be seen from this figure that the enhancement of radiation response is larger than that seen with either modality alone and results in an EF (12) of 1.6. Indeed, over the radiation dose range studied the response observed is similar to that obtained for SCCVII cells irradiated under aerobic conditions in vitro (Chaplin, unpublished studies) . The cell survival studies performed were complemented with growth delay studies which are shown in Figure 3 . The results obtained show that Nicotinamide and Fluosol DA enhance the amount of growth delay seen when administered before irradiation consistent with the cell survival work. However, combination of the two modalities results in a greater enhancement of radiation response and is consistent with a dose modification factor of between 1.5 and 2.0.
Subsequent to these studies we extended our investigation to evaluate the effects of Nicotinamide and/or Fluosol DA/ Carbogen on the radiation response of the KHT sarcoma. These studies were initiated by the finding that KHT tumours implanted subcutaneously exhibit similar microregional heterogeneity of oxygen delivery as that seen in the SCCVII tumour Minchinton et al., 1990) . The effect of Nicotinamide administered i.p. at a dose of 1.0 mg g-' 60 min prior to various doses of X-rays is shown in Figure 4 . It can be seen that Nicotinamide enhances radiation response, with an EF (12) of 1.3 being evident. A somewhat smaller effect is seen when Fluosol DA/Carbogen pretreatment is given, as can be seen from the cell survival studies shown in Figure 4 . Indeed, the enhance-1 o-'r ment of radiation induced cell killing does not attain significance at the dose level used (P is greater than 0.05) for either agent. The effect of combining Nicotinamide and the Fluosol DA/Carbogen pretreatments on radiation response of the KHT sarcoma is shown in Figure 4 . As with the SCCVII there is a clear indication that combining the two modalities results in a greater enhancement of tumour response. The EF (12) obtained from the data shown is 1.6. In order to further investigate the mechanism of action of Nicotinamide and Fluosol DA in the KHT Radiation dose (Gray) 
Discussion
The results obtained indicate that Nicotinamide and Fluosol DA/Carbogen are both able to sensitise the hypoxic cell compartment of SCCVII and KHT tumours to irradiaton. However, in this study the level of increased radiation induced killing produced by Fluosol DA/Carbogen did not attain statistical significance (i.e. P is greater than 0.05) in either tumour model. The EF (I 2)'s of approximately 1.1 -1.3 obtained with either modality alone are consistent with much of the previously reported data using these agents in other tumour systems (Teicher & Rose, 1984; Rockwell, 1985; Rockwell et al., 1986; Sasai et al., 1989; Horsman et al., 1987; Horsman et al., 1988; Horsman et al., 1989; . However, somewhat greater enhancements of radiation effects by Fluosol DA/Carbogen treatment have been reported in some systems (Song et al., 1985; Song et al., 1987; Teicher & Rose, 1986) . As alluded to in the introduction, the results obtained previously could be explained by each agent having its predominant effect on either the chronically or acutely hypoxic cell compartment.
There is evidence that in the two tumour systems used in the present study hypoxia can result at least in part from dynamic fluctuations in microregional blood flow Chaplin et al., 1986; Trotter et al., 1989 Minchinton et al.,-1990 ). This finding is consistent with previous reports indicating that Nicotinamide can result in an increase in tumour perfusion and reduction in the amount of hypoxia (Horsman et al., 1988; Horsman et al., 1989 Figure 5 has a marked sensitising effect on both bright and dim cell subpopulations, indeed, from the results shown it would appear that at this radiation dose little or no hypoxic response can be detected in either subpopulation. It I I I is an appealing assumption that combining an agent which modifies dynamic microregional fluctuation in oxygen delivery (Nicotinamide) with one that increases the oxygen delivery capacity of the blood (Fluosol DA/Carbogen) provides a complementary schedule for overcoming the 'acute' and 'chronic' hypoxia known to exist in certain tumours. Further detailed work in other tumour systems and in normal tissues is now required to further test the efficacy of this combination. The contribution of repair inhibition properties of Nicotinamide (Jonsson et al., 1985; Kjellen et al., 1986) has not been investigated in the present study. Although previous reports have indicated that such effects may be minimal in experimental tumours in vivo (Horsman et al., 1989) , further work is needed in this area, particularly in fractionated treatment schedules. Indeed, the combination of repair inhibition and increased tumour oxygenation would provide a double-edged sword for use in fractionated radiotherapy.
In conclusion, the present study indicates that the combination of Nicotinamide, Fluosol DA and Carbogen provides an effective strategy for increasing radioresponsiveness of hypoxic cells in vivo. Evidence is provided that one of the mechanisms responsible for this effect is a reduction of acute and chronic hypoxia within the tumour mass.
